NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on surgical treatments for neurological disorders, announced it will release financial results for its fiscal second quarter ended March 31, 2026, before market open on Tuesday, May 12, 2026. The company will host an investor conference call and webcast at 8:30 a.m. Eastern time that same day to discuss the results, provide a corporate update, and answer questions from participants.
The earnings call is significant for investors and industry observers as it will provide insights into NeuroOne's recent performance and future outlook. NeuroOne markets a minimally invasive, high-definition electrode technology platform with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System (for brain), and OneRF Trigeminal Nerve Ablation System. These products aim to reduce hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering both diagnostic and therapeutic functions.
To participate in the conference call, dial 888-506-0062 (toll-free within the U.S.) or 973-528-0011 (international) and use the participant access code 224785. A live webcast will be available at NMTC FY Q2 2026 Earnings Call Webcast. Participants should join at least five minutes before the start of the call.
A replay of the call will be available through Tuesday, May 26, 2026, by dialing 877-481-4010 (U.S.) or 919-882-2331 (international) using the replay passcode 53948. A webcast replay will also be accessible through the same link until Wednesday, May 12, 2027.
NeuroOne is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. For more information, visit nmtc1.com.
